Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Element Solutions Inc. Common Stock (ESI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Element Solutions Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Element Solutions Inc. Common Stock trades at $35.01 (market cap $9.07B). The key difference: Element Solutions Inc. Common Stock is far larger — about 3.2× Dyne Therapeutics Inc. Common Stock's market cap, and Element Solutions Inc. Common Stock pays a 0.86% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Element Solutions Inc. Common Stock for 6 Days on average.
| DYN | ESI | |
|---|---|---|
Market Cap | $2.81B | $9.07B |
Volume | 2,195,902 | 3,090,738 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $49.09 |
52-Week Low | $14.60 | $22.99 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $11.00B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Element Solutions (ESI) trades at $37.20, up 2.06% today, with a neutral technical signal and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats and robust revenue growth from $2.55B in 2025 to $3.2B projected for 2026. Recent developments include the termination of the Solstice merger and focus on AI-driven demand and operational efficiencies.
ESI presents a mixed outlook with strong fundamental growth offset by valuation concerns. The stock trades at a premium P/E of 50.27 with analyst consensus target of $47.90 suggesting 28.8% upside. Key risks include inflation pressures and uneven industrial demand, while catalysts include continued AI adoption and data center expansion driving future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Element Solutions Inc. Common Stock
Element Solutions provides specialty chemical products and technical services. Its solutions support electronics, communications, automotive systems, industrial surface finishing, and offshore energy.
Read more on ESI →
